Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Tumour Site

Malignant Germ-Cell Tumours of the Adult Male

Presenters

Sivasubramaniam Kumaravelu

Citation

Annals of Oncology (2020) 31 (suppl_6): S1319-S1324. 10.1016/annonc/annonc357

Authors

S. Kumaravelu, L. Kvs, S.K. Elumalai

Author affiliations

  • Medical Oncology, Madras Medical College, 600003 - Chennai/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 216P

Background

Seminomas form around 50% of germ cell tumours of testes. It commonly occurs during third decade. It is highly chemo sensitive and radio sensitive. Those patients who recur during surveillance for early stage can be salvaged by treatment with chemotherapy or radiotherapy most of the times.

Methods

Data was collected from master case sheets of seminoma patients treated over a period of five years from January 2013 to December 2017 at department of Madras medical college, Chennai.

Results

28 patients had seminoma of testes with a median age of 37 years. All patients had classical type histopathology. Right testis was more commonly involved (n=21) than left (n=7). 4 patients had seminoma arising from undescended testes. 10.7% (n=3) patients had elevated beta hcg and 28.5% (n=8) had elevated LDH. 9 patients had stage I, 12 patients had stage II and 7 patients had stage III disease. 3 patients had trans scrotal violation at peripheral hospital. 6 patients with stage I received paraaortic nodal irradiation with a mean dose of 24Gy of which 3 patients received inguinal irradiation also. All stage II and stage III patients received adjuvant chemotherapy with BEP regimen with minimum of 3 cycles. 2.5 year DFS and OS in stage I was 88.9% (n=8) and 100% (n=9) respectively. 2.5 year DFS and OS in stage II was 83.3% (n=10) and 91.6% (n=11) respectively. 2.5 year DFS and OS was 71.4% (n=5) and 71.4% (n=5) respectively.

Conclusions

Patients presented with advanced stage compared to that given in literature due to ignorance. Treatment results were comparable with that given in the literature.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Sivasubramaniam Kumaravelu.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.